Related Experiment Video
Updated: Jan 14, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Associations between antibiotics, proton pump inhibitors, NSAIDs and liver abscess
Hon-Yen Wu1, Chun-Ru Hsu2, Ping-Hsiu Tsai3
1Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan.
Objective:
Liver abscess (LA) caused by Klebsiella pneumoniae is endemic in Taiwan. This study aimed to clarify the associations between antibiotics, PPIs, and NSAIDs among patients hospitalized due to LA.
Methods:
This population-based, case-control study was conducted using the 2005 Longitudinal Generation Tracking Database of Taiwan's National Health Insurance, comprising 2 million insured individuals from 2000 to 2021. Individuals without LA were matched to adult LA patients by age and sex using propensity score matching (PSM). Exposure to antibiotics, PPIs, and NSAIDs within one year prior to diagnosis was assessed. Logistic regression analysis was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs).
Results:
After PSM, the data of 10,335 patients with liver abscess and 20,670 controls were analyzed. Within 7 days prior to hospitalization, univariate analysis showed significantly higher ORs of LA associated with 2nd/3rd generation cephalosporins (OR 181.91, 95 % CI 58.5-566.1), 1st generation cephalosporins (OR 18.5, 95 % CI 9.6-35.5), NSAIDs (OR 17.0, 95 % CI 11.7-24.8), amoxicillin/ampicillin with beta-lactamase inhibitors (OR 15.0, 95 % CI 7.5-30.0), PPIs (OR 9.5, 95 % CI 6.4-14.0), and fluoroquinolones (OR 9.2, 95 % CI 5.6-15.1). Multivariable logistic regression revealed that associations between LA and medication use persisted for NSAIDs, 2nd/3rd generation cephalosporins, and amoxicillin/ampicillin with beta-lactamase inhibitors up to one year prior to hospitalization.
Conclusion:
PPIs, NSAIDs, and some antibiotics are significantly associated with increased risk of LA, necessitating cautious medication use.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

